Clinical Trials
74 trialsNCT03125928 2026-05-22
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Fox Chase Cancer Center
Phase 2 Active not recruiting
NCT06445400 2026-05-13
A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT07413939 2026-05-11
BREnnA
Hoffmann-La Roche
Phase 2/3 Recruiting
NCT06968585 2026-05-08
A166
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT05705401 2026-04-27
HERO
NRG Oncology
Phase 3 Active not recruiting
NCT07518173 2026-04-08
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT03975647 2026-03-30
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT07043725 2026-03-27
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT07377643 2026-02-25
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 3 Recruiting
NCT04273555 2026-02-06
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
University of Alabama at Birmingham
Phase 1/2 Withdrawn
NCT06830889 2026-01-22
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07281001 2025-12-15
Traderrus
Blokhin's Russian Cancer Research Center
Phase NA Recruiting
NCT03571633 2025-11-26
BREASTIMMU02
Centre Leon Berard
Phase 2 Active not recruiting
NCT05982678 2025-11-26
ANISE
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT04419181 2025-10-14
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
University of Rochester
Phase 2 Withdrawn
NCT06891833 2025-10-02
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Recruiting
NCT07198672 2025-09-30
Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag
Henan Cancer Hospital
Phase NA Not yet recruiting
NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT07166367 2025-09-10
Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer
National Cancer Centre, Singapore
Phase 2 Terminated
NCT03588091 2025-08-22
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT06316531 2025-08-19
A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT07116824 2025-08-12
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT07115095 2025-08-11
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
Shaanxi Provincial Cancer Hospital
Phase NA Completed
NCT06123988 2025-08-06
FastER
University of Miami
Phase NA Recruiting
NCT06973525 2025-08-05
HER2-DM-NACT
Hebei Medical University Fourth Hospital
Phase 2 Not yet recruiting
NCT06992882 2025-07-18
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
Fudan University
Phase 3 Recruiting
NCT05514717 2025-07-11
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Mersana Therapeutics
Phase 1 Recruiting
NCT05511844 2025-07-04
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Orum Therapeutics USA, Inc.
Phase 1 Terminated
NCT04332588 2025-05-29
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
University of Alabama at Birmingham
Phase 1 Recruiting
NCT03460067 2025-03-27
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
University of Kansas Medical Center
Phase NA Active not recruiting
NCT05955170 2025-03-27
TUC-TOC
Institut Curie
Phase 2 Recruiting
NCT06832904 2025-02-18
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT05306041 2025-02-17
GeparPiPPa
GBG Forschungs GmbH
Phase 2 Recruiting
NCT05555251 2024-12-16
CONTRAST
BioInvent International AB
Phase 1/2 Terminated
NCT06718335 2024-12-11
Pyrotinib in HER2-positive Early Breast Cancer
Yunnan Cancer Hospital
Phase NA Not yet recruiting
NCT05426486 2024-10-30
A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Phase 2/3 Active not recruiting
NCT06548178 2024-08-12
T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
Fudan University
Phase 2 Not yet recruiting
NCT05710666 2024-08-05
Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study)
Cancer Trials Ireland
Phase 2 Active not recruiting
NCT04957212 2024-07-26
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
Cinnagen
Phase 3 Completed
NCT05635487 2024-07-05
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients
Shengjing Hospital
Phase 2 Recruiting
NCT06313086 2024-05-10
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Recruiting
NCT03330561 2024-04-22
PRS-343 in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
Phase 1 Completed
NCT03650348 2024-04-22
PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
Pieris Pharmaceuticals, Inc.
Phase 1 Completed
NCT06330012 2024-03-26
The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.
Samsung Medical Center
Phase NA Recruiting
NCT03709082 2024-03-05
Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
University of Kansas Medical Center
Phase 1/2 Terminated
NCT06217185 2024-02-28
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Hebei Medical University Fourth Hospital
Phase 4 Recruiting
NCT06107790 2023-10-30
Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer
Zhejiang Hisun Pharmaceutical Co. Ltd.
Phase 3 Completed
NCT03953833 2023-09-14
B003-101
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1 Completed
NCT05985187 2023-08-14
Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT05945368 2023-07-14
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown